Background and aims Using smoking cessation medications for several weeks prior to quitting smoking facilitates quit-
INTRODUCTION
The medications that are currently licensed for smoking cessation (nicotine replacement therapy (NRT), bupropion and varenicline) are likely to work along somewhat different physiological pathways, but they have similar effects on smokers in that they all reduce the intensity and frequency of urges to smoke. This effect can have two discrete manifestations, with different treatment implications.
1. The medications alleviate withdrawal discomfort after a smoker has stopped smoking [1] [2] [3] . This was the effect that originally allowed the medicinal licensing of NRT because medicinal regulations required that a drug affects a disease or a symptom; 'craving reduction' satisfied the latter requirement ('nicotine dependence' became officially a disease only after the publication of DSM-III in 1980). Partly because of this focus on post-cessation urges to smoke, and partly because of concerns about nicotine overdose if NRT was used while smokers still smoked, NRT was provided only after smokers quit smoking in the initial licensing. Later licensing of the other two medications, bupropion and varenicline, followed a similar pattern. Although bupropion and varenicline are used for 7-14 days prior to quitting, this is to allow patients to habituate to medication effects and dose increases rather than aimed at increasing treatment effects. 2. In contrast to the post-quit effects, both NRT and varenicline, and probably also bupropion, also exert their 'craving reduction' effects while smokers still smoke [4] [5] [6] [7] . This might also assist with smoking cessation. Attempts have been made to harness this effect by instigating medication use over a period of time prior to the target quit day (TQD) while smokers smoke ad libitum (an intervention that has become known as pre-loading). In theory, this approach can enhance the efficacy of post-TQD treatment, as discussed below, but it has not been studied extensively to date. Varenicline and bupropion pre-loading demonstrated encouraging short-term effects in three small trials [6] [7] [8] , while the results of NRT pre-loading have been more mixed [9, 10] . This could be due in part to some studies combining pre-loading with smoking reduction [11, 12] , a combination that may undermine the effect of pre-loading by reducing the opportunities for extinction learning (smoking with diminished rewards) and increasing the rewarding value of the remaining cigarettes. However, this is only a hypothesis. Although, for example, the pioneering trial by Rose et al. found pre-loading with ad libitum smoking instructions effective [13] , another trial found no difference in outcomes in groups smoking their usual or reduced nicotine cigarettes for 2 weeks pre-quit ( [4] ; and a factorial experiment found a synergistic benefit of pre-quit patch use and pre-quit counselling that included a smoking reduction component, although there was no study arm with a counselling that omitted this or encouraged ad libitum smoking [14, 15] .
We recently completed a large randomized trial of 4 weeks pre-loading with nicotine patches where participants were encouraged to smoke ad libitum during the pre-loading period; pre-loading facilitated quitting [16] .
The trial provides an opportunity to examine the putative 'active ingredients' of the pre-loading intervention. Pre-loading could, in theory, facilitate quitting in several distinct ways. Smokers may experience fewer urges to smoke (e.g. because the relevant receptors are stimulated by nicotine from NRT or occupied by varenicline), and this reduction of learned association between smoking behaviour and withdrawal relief (extinction of negative reinforcement) may facilitate quitting later. A reduced drive to smoke may also mean that a person will not smoke when they normally would, and in response to the usual smoking cues, which may weaken the power of the cues and situations to elicit a smoking response later. Pre-loading may also facilitate reduction of the enjoyment of smoking, i.e. positive reinforcement from smoking. Quitting a behaviour which by now provides limited satisfaction could be significantly easier than if smokers were quitting without preloading. The mechanisms described above could all reduce frequency and/or intensity of smoking, with such an extinction possibly occurring without much subjective experience of positive or negative effects. One consequence of all the above could be reduced cigarette dependence. Aside from these addiction-based mechanisms, three additional hypotheses can be formulated. Pre-loading may increase self-efficacy by generating a reduction in smoking with little effort. It may also assist with getting used to and in the habit of using the medication, and this could improve medication adherence after TQD. Finally, in a recent trial (Przulj et al. submitted) we noticed that a proportion of participants who pre-loaded with patches reported developing an aversion to cigarettes. This was presumably because smoking increased systemic nicotine levels to the level that generates nausea and thus made smoking aversive. Aversion to cigarettes could thus be another mediator of the effects of pre-loading, as aversive smoking is an effective cessation technique [17] . Understanding the mechanism of action has important theoretical implications, but may also lead to a more effective use of this novel treatment. If pre-loading is only effective in people who show early changes in relevant mediators, it could be stopped if the strategy is not achieving its intermediate effects. This would save resources and allow early implementation of alternative treatments. An insight into the mechanism of action can also lead to improvements in effectiveness. If, for instance, pre-loading works by making smoking aversive, increasing the medication dose could improve efficacy, while if extinction is the main mechanism, extending the pre-loading period could be helpful, etc.
In this report, we use the data from the pre-loading trial to examine a range of possible effects of pre-loading on: (1) positive reward from smoking, (2) negative reward (alleviating boredom, calming effects, etc.), (3) the intensity of urges to smoke, (4) smoking sterotypy, (5) cigarette consumption and smoke intake, (6) self-efficacy, (7) nausea and aversion to smoking, (8) post-TQD urges to smoke and cigarette withdrawal symptoms and (9) post-TQD medication use. We conducted mediation analysis using the causal inference approach to investigate the assumed causal pathways underlying the intervention.
METHODS

Design
In the main trial, participants were randomized to either standard smoking cessation medications accompanied by behavioural support or the same treatment supplemented by nicotine 'pre-loading', i.e. 4 weeks of 21-mg nicotine patch use prior to quitting. Potential mediators were assessed at baseline and 1 week into the pre-loading (3 weeks prior to quitting), and urges to smoke were also assessed in abstainers 1 week after the target quit date. We examined the effect of potential mediators on abstinence at 4 weeks and 6 months post-TQD using path analysis [18] . Participants were enrolled between 13 August 2012 and 10 March 2015.
Main trial and its results
For trial details, see The Preloading Investigators [16] and Lindson-Hawley et al. [19] . In brief, this was an open-label trial with 1792 smokers randomized 1 : 1 to non-use (n = 893) or use (n = 899) of a nicotine patch for 4 weeks prior to quit day. It was a multi-centre trial with study sites at Nottingham, Birmingham, Bristol and London. Participants used standard pharmacotherapy of their choice, including NRT products, varenicline or bupropion, with NRT starting on TQD while the other medications began 1-2 weeks earlier, as per usual practice. They also received the standard behavioural support as provided by the Stop Smoking Service (SSS), that typically comprises weekly support sessions over at least 4 weeks [20] . The primary outcome was prolonged biochemically validated abstinence at 6 months. Participants lost to follow-up or not providing biochemical validation were included as non-abstainers. In this open-label trial with no placebo control, participants assigned to patch pre-loading were less likely to use varenicline than the control group. As in other trials (e.g. [21, 22] ), varenicline use was associated with significantly higher quit rates than NRT use. When controlling for this imbalance, as pre-specified in the trial protocol, the intervention showed a significant effect on smoking cessation at 1, 6 and 12 months with odds ratios (OR) of 1.32 [95% confidence interval (CI) = 1.08-1.62], 1.34 (95% CI = 1.03-1.73) and 1.36 (95% CI = 1.02-1.80), respectively. The preloading intervention comprising a provision of patches for 4 weeks prior to TQD appeared to be safe and well tolerated.
Study arms
In the intervention arm, participants were asked to wear a 21-mg 24-hour nicotine patch daily for 4 weeks prior to quit day. They were asked to smoke as normal, and received a booklet outlining the rationale for the intervention and adherence support.
We planned initially to use placebo patches in the control arm, but the funders did not allow this. To provide a plausible alternative, we asked participants to monitor their smoking pattern over the same time-period, noticing the triggers for particular cigarettes, and to plan ways to avoid these cues after quit day. The control arm received a booklet outlining this process, which was similar in length and appearance to the booklet given to the intervention group.
Both study arms were referred to the local SSS, where a TQD was set between 3 and 5 weeks after enrolment. The Service provides 'withdrawal-oriented treatment' [23] that comprises licensed medications (NRT-usually in combinations of patches and short-acting NRT forms, varenicline or bupropion-with these two medications normally not combined with NRT) together with weekly behavioural support starting 1-2 weeks prior to quit day and continuing until at least 4 weeks after quit day. The medications were provided for up to 3 months. The study protocol allowed use of all stop-smoking medication regardless of pre-loading, necessitating a period of concomitant use of varenicline and bupropion together with patches for 1-2 weeks pre-TQD.
Timing of assessments
Participants were seen by researchers at baseline to collect data on mediators and to instigate interventions. We reassessed participants 1 week later and again 1 week after their TQD, 5 weeks after commencing pre-loading. The aim of these assessments was to assess mediators, described below, and monitor adverse effects. Data on abstinence were collected at 4 weeks, 6 and 12 months post-TQD. Four-week outcome data were provided by the SSS, who validate abstinence by exhaled air carbon monoxide (CO) concentration. At 6 and 12 months after the TQD, we telephoned participants and invited those who claimed to be abstinent for at least a week to provide an exhaled CO reading. Participants were compensated £15 for their time for attending this meeting.
MEASURES
We report both 4-week and 6-month outcomes but, given that the former follow-up point is more proximate to the mediator variables we were studying, the primary focus was on 4-week smoking status. Abstinence was defined as no smoking at all for the previous 2 weeks validated by CO reading of < 10 parts per million (p.p.m.).
Potential mediator variables were first measured 1 week after the start of pre-loading. Some measures related to responses to smoking were not included after quit day. The measures were as follows:
Positive reinforcement: modified Cigarette Evaluation Questionnaire (mCEQ) Satisfaction Subscale [24] . This comprises four items concerning satisfaction and enjoyment of smoking with scores ranging from 1 = not at all to 7 = extremely. Participants also rated whether their cigarettes were more or less enjoyable than previously. Negative reinforcement: mCEQ Reward Subscale. This comprises five items on whether smoking reduces irritability, provides a calming effect, etc. with scores ranging from 1 = not at all to 7 = extremely. Drive to smoke: ratings of strength and frequency of urges to smoke in the Mood and Physical Symptoms Scale Craving subscale (MPSS-C) [25] , with scores ranging from 1 = not at all to 6 = extremely/all the time, and a question from a previous trial that asked participants to rate their urge to smoke compared with usual [6] , with scores ranging from 1 = much weaker to 5 = much stronger; and ratings of other MPSS items including depression, irritability, restlessness, poor concentration and hunger (MPSS-M) [25] . We also analysed the mCEQ craving question ('did smoking it immediately relieve your craving for a cigarette?', scored as other mCEO items). We also included the Fagerström Test of Nicotine Dependence (FTND) with the question about cigarette consumption removed, as this was assessed directly as smoking behaviour. As withdrawal scores from people who continue to smoke are difficult to interpret [25] , we analysed these after quit day only in participants who had remained abstinent or were continuing to try to be abstinent. Smoking stereotypy: this comprised two items from the Nicotine Dependence Syndrome Scale (NDSS) [26] : 'I feel a sense of control over my smoking. I can "take it or leave it" at any time' and 'my smoking is not much affected by other things. I smoke about the same amount whether I'm relaxing or working, happy or sad, alone or with others, etc.', with scores ranging from 1 = not at all true to 5 = extremely true. (The other NDSS items relate to the amount smoke, that we measured directly.) Changes in smoking behaviour: reduction in cigarettes per day and in CO reading. Post-TQD medication adherence: days of use of post-quit day medication measured at 1 week post-TQD. Self-efficacy: 'how high would you rate your chances of giving up smoking for good at this attempt?', with scores ranging from 1 = not at all to 5 = extremely. Nausea and aversion during pre-loading: 'over the past week, how nauseous have you felt when you have seen cigarettes or lighters' and 'over the past week, how nauseous have you felt when you have smelt cigarette smoke?', with scores ranging from 1 = not at all to 5 = extremely. Aversion was measured using the aversion subscale of the mCEQ that comprises two items asking whether smoking caused dizziness and nausea, scored as other mCEQ items above.
Statistical analysis
Mediation analysis was performed using the methods described by Valeri & Vanderweele [18] to investigate the direct and indirect effects of pre-loading treatment on cessation at 4 weeks and 6 months. Initially, baseline characteristics were compared descriptively, and smoking outcomes at 1 week, 4 weeks and 6 months were compared descriptively, using logistic regression to adjust for differences in varenicline use (pre-specified in the trial protocol). We then tested the direct effect of treatment on each potential mediator (path 'a'), using linear regression (analysis of covariance) to adjust for the baseline value of the mediator where appropriate. As a variable can only be a mediator of treatment if there is a significant effect (P < 0.05) of treatment on the mediator (path 'a'), subsequent mediation models were only fitted to variables that were associated significantly with pre-loading treatment. To test the indirect (mediating) effect ('ab' path), we used the -paramedcommand in Stata to fit a logistic regression model to the cessation outcomes, with treatment and the relevant mediator included as covariates, and a linear regression model to the mediator including treatment as a covariate. In these models the mediators were fitted as the change from baseline (in accordance with our hypothesis that it is the change from baseline which may mediate the observed treatment effect). The direct and indirect effects are then calculated from the coefficients of these models. The direct effect is interpreted as the influence of the intervention on the outcome that is not mediated by other variables in the model. More importantly, the indirect (mediated) effect expresses the portion of the treatment effect that is mediated through the specific mediator. This is estimated by how much the outcome would change if everyone in the study had the intervention and the mediator changed from its natural level had each individual been assigned to the control, to its natural level had each individual been assigned to treatment [27] . We also looked at the effect of adjusting for varenicline use measured at 1 week post-quit date as a binary indicator, as this was a potential confounder which differed between treatment groups. Table 1 shows sample characteristics including the baseline values of mediators.
RESULTS
Effects of pre-loading intervention on potential mediators
One week after the start of pre-loading
The effects of pre-loading on potential mediators are shown in the first part of Table 2 . Pre-loading reduced both positive and negative reward from smoking. It also reduced three of the four measures of drive to smoke (there was no effect on MPSS mood symptoms). There was a modest but significant reduction in self-reported cigarette consumption (by three cigarettes/day, from a baseline mean of 19) and reduction in exhaled CO of 3 ppm (from a baseline mean of 24 ppm). The FTND score excluding cigarette consumption also decreased. Both markers of aversion to smoking increased due to pre-loading. There was no evidence that confidence in quitting improved due to pre-loading.
One week after TQD
Pre-loading was associated with a significant reduction in urges to smoke. There was no effect on withdrawal mood symptoms or on participants' confidence in their ability to quit smoking. Unlike in the pre-quit period, there was no evidence of a difference in nausea on seeing cigarettes after the quit day. There was also no evidence that pre-loading improved adherence to post-cessation medication; see Table 2 .
Association between mediators and smoking abstinence Table 3 shows the results of path analysis regarding abstinence at 4 weeks and Table 4 shows the effects at 6 months.
Regarding objective effects, the reduction in exhaled CO was a significant mediator of the effect of pre-loading on abstinence at 4 weeks but narrowly missed significance at 6 months. The indirect effect suggests that smoking cessation would be increased by 4% if each participant reduced their CO reading by an average of 3.2 (as given in Table 2 ).
Among subjective ratings, rating urges to smoke as weaker than usual at À3 weeks was a significant mediator of the effect of pre-loading on abstinence at both 4 weeks and 6 months after adjustment for varenicline use. The indirect effect suggests that smoking cessation would be increased by 12% at 4 weeks and 16% at 6 months if each participant's urges were reduced by an average of À0.8 on a five-point scale (as seen in Table 2 ).
The reduction in urges to smoke assessed by MPSS at +1 week was also a significant mediator of the effect at both 4 weeks and 6 months. The indirect effect suggests that smoking cessation would be increased by 5% if urges to smoke were reduced by 0.2 points at 1 week post-TQD (as in Table 2 ).
Cigarette consumption, enjoyment, reward, craving, satisfaction, smoking stereotypy and aversion had no significant mediating effects at 4 weeks or 6 months.
DISCUSSION
The pre-loading intervention affected a number of potential mediators, but there was evidence that only three of them mediated the effect of pre-loading on abstinence: the reduction in urges to smoke and reduction in smoke intake indexed by reduced CO readings 1 week after the start of pre-loading and reduced urges to smoke post-quit.
The study has several limitations. Key data on potential mediators were collected 1 week after commencing treatment. This was dictated by pragmatic considerations, as the session was scheduled to allow early safety monitoring and dosing adjustment. However, logic and previous trials suggest that the effects of pre-loading on relevant variables increases with duration [6] , and we may have seen stronger associations between pre-loading and change in mediators and between change in mediators and abstinence if this assessment had taken place later. Trial logistics, however, precluded more frequent contacts. Also, the timing of the assessments had the advantage of taking place at the stage when the largest number of participants might have been expected to adhere to pre-loading instructions and remain engaged in the trial. Another limitation is that the open-label nature of the trial leaves open the possibility that some of the effects we detected were the result of participants' expectations. Participants in the intervention arm were told about the proposed mechanism of preloading to motivate them to adhere to the medication, and this or other types of expectations may have influenced their questionnaire responses. We provided the control arm with a credible self-monitoring intervention to mitigate any expectation effects, but it is not clear if this increased positive expectations and whether it could have affected some of the variables we examined. These issues, however, would be less likely to affect objective measures or measures collected post-quit. It is also reassuring that the two study arms did not differ in self-efficacy, which could be expected to be sensitive to expectation effects. We monitored a number of variables, and although these were based on defined pathways, the results should be regarded as exploratory as we were testing several competing hypotheses.
The finding related to reduced urges to smoke among those continuing their quit attempt at 1 week post-TQD needs to be interpreted with caution. Although those who had returned to smoking were excluded in both study arms, which reduces the risk of bias, abstinence status was influenced by the intervention, and the finding therefore reflects the mediating effect in a subset of the original sample.
The study has several strengths. We planned a comprehensive evaluation of the mechanism of action, assessing the full range of possible steps in the pathway, and we included analyses of competing hypotheses that have been advanced to explain the pre-loading effect. We also collected a comprehensive range of relevant variables. Finally, Data represent the mean across items taken for all scales. a n varies due to missing data; b adjusted for baseline (where appropriate) to provide an estimate of the difference in change from baseline between groups; c at week +1 (1 week after quit day), the sample comprises only those who were abstinent or still trying to quit. CO = carbon monoxide; FTND = Fagerström Test for Nicotine Dependence; mCEQ = Modified Cigarette Evaluation Questionnaire; MPSS = Mood and Physical Symptoms Scale; SD = standard deviation. MPSS-C is the MPSS craving subscale; MPSS-M is the MPSS subscale including five 'mood' items. our trial included strict outcome measures and long-term follow-up and, to our knowledge, it is by far the largest trial of pre-loading to date.
Some, but not all, of our findings tally with previous studies. Unlike some previous studies [28] , we found that pre-loading reduced both positive and negative reward from smoking. Our trial is much larger than its predecessors, and it is possible that previous trials may have missed the effect. In a previous study of pre-loading with varenicline, there was a marked effect on enjoyment of smoking. This was considered to be one of the active ingredients of pre-loading treatments, although no mediator analysis was performed [6] . Although, in this study, preloading reduced smoking rewards as well, this did not The controlled direct effect (CDE) expresses how much the outcome would change on average if the mediator were controlled at level m uniformly in the population, but the treatment were changed from control to treatment. The natural indirect effect (NIE) expresses how much the outcome would change on average if everyone received treatment but the mediator were changed from the level it would take on control to the level it would take on treatment. The total effect (TE) is defined as how much the outcome would change overall for a change in the exposure from control to treatment. CO = carbon monoxide; FTND = Fagerström Test for Nicotine Dependence; mCEQ = Modified Cigarette Evaluation Questionnaire; MPSS = Mood and Physical Symptoms Scale. MPSS-C is the MPSS craving subscale.
mediate treatment effects. The main mediator was the reduction of urges to smoke. Varenicline pre-loading may have different effects to NRT pre-loading. Another possibility is that reduced enjoyment of smoking, while in this case not a significant mediator of abstinence on its own, could have still contributed indirectly, via urge reduction. Urge to smoke can be seen as consisting of a 'push' driven by an internal need and a 'pull' via expected reward. In this hypothesis, blunting the reward could contribute to lowering the urge. In any case, the reduced drive to smoke appears to be the best candidate mechanism for the effect of pre-loading. The main objective mediator of treatment effects was reduced smoke intake. This can be interpreted as a The controlled direct effect (CDE) expresses how much the outcome would change on average if the mediator were controlled at level m uniformly in the population, but the treatment were changed from control to treatment. The natural indirect effect (NIE) expresses how much the outcome would change on average if everyone received treatment but the mediator were changed from the level it would take on control to the level it would take on treatment. The total effect (TE) is defined as how much the outcome would change overall for a change in the exposure from control to treatment. CO = carbon monoxide; FTND = Fagerström Test for Nicotine Dependence; mCEQ = Modified Cigarette Evaluation Questionnaire; MPSS = Mood and Physical Symptoms Scale. MPSS-C is the MPSS craving subscale.
consequence of reduced drive to smoke. This is an interpretation of the results that seems plausible to us, but other interpretations may be possible. The findings have implications for clinical practice and for future research. If pre-loading were to be used routinely in smoking cessation treatments, therapists could monitor its early effect by asking users whether they have experienced reduced urge to smoke and by measuring CO levels, which is routine in most smoking cessation treatment centres. This would allow replacing pre-loading with other interventions if it appears to have no early effect. In terms of future work, if the main active ingredient is a reduction in the drive to smoke, both increasing the nicotine dose and extending the preloading period could increase treatment effects and warrant further investigation.
In summary, nicotine pre-loading appears to work because it reduces urges to smoke both prior to quitting and after smoking cessation.
Clinical trial registration
Current Controlled Trials, ISRCTN33031001.
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